ArticleMolecular psychiatry2021

Druggable genome in attention deficit/hyperactivity disorder and its co-morbid conditions. New avenues for treatment.

Tor-Arne Hegvik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.